A multiplex test that can analyze tumors for over 200 genes is now available from Foundation Medicine Inc., the Wall Street Journal reported today. The test will be used by Novartis, Sanofi SA, Johnson & Johnson and Celgene to analyze patients in early-stage clinical trials of new cancer drugs to identify patients most likely to benefit from the drug and to accelerate the drug approval process. An example of an expedited approval using genetic testing is the approval of the drug Xalkori developed by Prizer, Inc. to treat patients with a rare form of lung cancer. The cancer has been linked to a gene called ALK. Pfizer used the correlation and a genetic test for the marker to quickly select patients most likely to benefit from the treatment. The drug was approved in just four years based on studies involving a total of 255 patients. This is a significant advancement. Historically, it is reported that the cost to develop a new drug takes up to a decade, thousands of patients and $1 billion in research and development.
There are several tests on the market that analyze a single gene, one at time or maybe a handful of genes. However, just testing one gene isn’t enough in complex diseases like cancer which are now known to involve the interaction of many genes. Dr. William Pao, director of personalized cancer medicine at Vanderbilt University Medical Center, Nashville, Tennesee noted that testing patients for each gene related to a cancer or therapy would be “very onerous, expensive and time-consuming. The nice thing about platforms like the one Foundation has is that it detects all of them at the same time.”
The Journal reported that a commercial version of the test was made available last week with a list price of $5,800.
This blog is made available by Foley & Lardner LLP (“Foley” or “the Firm”) for informational purposes only. It is not meant to convey the Firm’s legal position on behalf of any client, nor is it intended to convey specific legal advice. Any opinions expressed in this article do not necessarily reflect the views of Foley & Lardner LLP, its partners, or its clients. Accordingly, do not act upon this information without seeking counsel from a licensed attorney.
This blog is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Communicating with Foley through this website by email, blog post, or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material you transmit to Foley through this blog, whether by email, blog post or any other manner, will not be treated as confidential or proprietary.
The information on this blog is published “AS IS” and is not guaranteed to be complete, accurate, and or up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other guarantees, warranties, conditions and representations of any kind, either express or implied, whether arising under any statute, law, commercial use or otherwise, including implied warranties of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise), to you or anyone else, for any claims, losses or damages, direct, indirect special, incidental, punitive or consequential, resulting from or occasioned by the creation, use of or reliance on this site (including information and other content) or any third party websites or the information, resources or material accessed through any such websites.
In some jurisdictions, the contents of this blog may be considered Attorney Advertising. If applicable, please note that prior results do not guarantee a similar outcome. Photographs are for dramatization purposes only and may include models. Likenesses do not necessarily imply current client, partnership or employee status.